Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.

PloS one - 1 Jan 2017

Matossian Margarite D, Elliott Steven, Hoang Van T, Burks Hope E, Phamduy Theresa B, Chrisey Douglas B, Zuercher William J, Drewry David H, Wells Carrow, Collins-Burow Bridgette, Burow Matthew E

Abstract excerpt

Triple negative breast cancers (TNBCs) have high recurrence and metastasis rates. Acquisition of a mesenchymal morphology and phenotype in addition to driving migration is a consequential process that promotes metastasis. Although some kinases are known to regulate a mesenchymal phenotype, the role for a substantial portion of the human kinome remains uncharacterized. Here we evaluated the Published Kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transdifferentiation
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial Cells

Share to Mesoderm

Share to Molecular Targeted Therapy

Share to Small Molecule Libraries

Share to Triple Negative Breast Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 28771473
DOI: 10.1371/journal.pone.0177802
PMCID: PMC5542472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.PMID 28771473Read ↗

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast CancerSemantic proximity Read ↗

NEK5 Activity Regulates the Mesenchymal and Migratory Phenotype in Breast Cancer CellsSemantic proximity Read ↗

Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Semantic proximity Read ↗

Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast CancerSemantic proximity Read ↗

Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous diseaseSemantic proximity Read ↗

NEK5 activity regulates the mesenchymal and migratory phenotype in breast cancer cells.Semantic proximity Read ↗

Mitotic kinases are emerging therapeutic targets against metastatic breast cancerSemantic proximity Read ↗

Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system.Semantic proximity Read ↗

Whole transcriptome analysis reveals ELK3 as a key driver of metastasis through regulation of 3D migration and stemness in triple-negative breast cancer cellsSemantic proximity Read ↗

The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cellsSemantic proximity Read ↗

Targeting the Breast Cancer KinomeSemantic proximity Read ↗

Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.